Tags : Rheumatology

Fresenius Kabi’s Idacio (adalimumab, biosimilar) Receives EU’s Marketing Approval in

Shots: The approval is based on its non-inferiority data consisting of its PK, efficacy, safety, immunogenicity data with the reference product in analytical, preclinical and clinical data trials Fresenius Kabi has a portfolio consisting of generic drugs, infusion therapies, biosimilars, and clinical nutrition products focusing on multiple therapy areas Idacio (adalimumab, biosimilar) is a mAb […]Read More